Phenotype-informed selection of microbiota-directed interventions in irritable bowel syndrome: current evidence and limitations
- 1Department of Nutrition, Faculty of Medicine of Monastir, EPS Fattouma Bourguiba
Abstract
Irritable bowel syndrome (IBS) is a heterogeneous disorder of gut–brain interaction in which bowel-habit subtype, dominant symptoms, post-infectious onset, bile-acid handling, visceral sensitivity, and diet–microbiota interactions may influence the treatment response. This narrative mini-review asks whether available clinical evidence is sufficient to select or sequence microbiota-directed and microbiota-modulating interventions according to Rome bowel-habit subtype and clinically observable dominant symptoms. Literature was identified through PubMed/MEDLINE and major guidelines, systematic reviews, meta-analyses, and pivotal trials published through June 2026. Evidence was interpreted at the level of the exact intervention or product, studied population, target outcome, consistency, independent replication, safety, and guideline position. Mechanistic data support plausible links through fermentation, epithelial barrier function, mucosal immunity, bile-acid metabolism, visceral sensitivity, and gut–brain signaling, but mechanistic or microbiome changes do not establish the clinical efficacy. Rifaximin has the clearest replicated and guideline-supported role in IBS with diarrhea, while soluble fiber has guideline support for global or constipation-associated symptoms. Evidence for individual probiotics, postbiotics, partially hydrolyzed guar gum, galactooligosaccharides, and fermented matrices remains product-specific or emerging and is rarely independently replicated. Symptom improvement with a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low-FODMAP diet) does not establish microbiota mediation. Fecal microbiota transplantation (FMT) and microbiome-guided prescribing remain investigational. Current evidence, therefore, supports only limited phenotype-informed matching and does not establish a validated treatment sequence or microbiome-defined therapeutic phenotype.
Related
- Gut Microbiota Profiles in Diarrhea-Predominant Irritable Bowel Syndrome and Their Relationship to Clinical Efficacy of Hangeshashinto: The GMIBS-HA Study.
- Xifenghuashi formula ameliorates diarrhea predominant-irritable bowel syndrome by modulating the gut microbiota and the bile acid-FXR-FGF axis: A human trial and an animal experiment
- Pharmacological and non-pharmacological strategies targeting HIF signaling and hypoxia tolerance: opportunities and limitations for personalized interventions
- Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning
- Differential physical activity responses to diabetes risk reduction interventions according to prediabetes phenotype in at-risk individuals: pooled analysis from three randomised controlled trials
BibTeX
@article{sallem2026phenotypeinformed,
title = {{Phenotype-informed selection of microbiota-directed interventions in irritable bowel syndrome: current evidence and limitations}},
author = {Om Kolthoum Sallem},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1921349},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1921349/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Phenotype-informed selection of microbiota-directed interventions in irritable bowel syndrome: current evidence and limitations
AU - Om Kolthoum Sallem
PY - 2026
DA - 2026/10/13
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1921349
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1921349/full
AB - Irritable bowel syndrome (IBS) is a heterogeneous disorder of gut–brain interaction in which bowel-habit subtype, dominant symptoms, post-infectious onset, bile-acid handling, visceral sensitivity, and diet–microbiota interactions may influence the treatment response. This narrative mini-review asks whether available clinical evidence is sufficient to select or sequence microbiota-directed and microbiota-modulating interventions according to Rome bowel-habit subtype and clinically observable dominant symptoms. Literature was identified through PubMed/MEDLINE and major guidelines, systematic reviews, meta-analyses, and pivotal trials published through June 2026. Evidence was interpreted at the level of the exact intervention or product, studied population, target outcome, consistency, independent replication, safety, and guideline position. Mechanistic data support plausible links through fermentation, epithelial barrier function, mucosal immunity, bile-acid metabolism, visceral sensitivity, and gut–brain signaling, but mechanistic or microbiome changes do not establish the clinical efficacy. Rifaximin has the clearest replicated and guideline-supported role in IBS with diarrhea, while soluble fiber has guideline support for global or constipation-associated symptoms. Evidence for individual probiotics, postbiotics, partially hydrolyzed guar gum, galactooligosaccharides, and fermented matrices remains product-specific or emerging and is rarely independently replicated. Symptom improvement with a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low-FODMAP diet) does not establish microbiota mediation. Fecal microbiota transplantation (FMT) and microbiome-guided prescribing remain investigational. Current evidence, therefore, supports only limited phenotype-informed matching and does not establish a validated treatment sequence or microbiome-defined therapeutic phenotype.
SN - 1663-9812
ER -